title: Worsening of psoriasis with rituximab therapy.
authors.forename: I
authors.initials: I
authors.lastname: Olivieri
authors.forename: S
authors.initials: S
authors.lastname: D'Angelo
authors.forename: P
authors.initials: P
authors.lastname: Leccese
authors.forename: D
authors.initials: D
authors.lastname: Vertone
authors.forename: A
authors.initials: A
authors.lastname: Olivieri
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D011565:Psoriasis / Q000139:chemically induced* / Q000175:diagnosis; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone